TOR1A: The Potential Drug Target and Biomarker (G1861)

Target Name: TOR1A

NCBI ID: G1861

TOR1A

TOR1A: The Potential Drug Target and Biomarker

TOR1A is a gene that has been identified as a potential drug target in the field of neurodegenerative diseases. Its full name is TOR1A-伪 and it is a key regulator of the protein translation factor eIF4E. TOR1A plays a crucial role in the development and progression of various neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

The TOR1A gene was first identified in 2004 and has been extensively studied to understand its function in neural development and disease. It is located on chromosome 18 and has been shown to be involved in the regulation of several cellular processes that are important for brain development and function.

One of the key functions of TOR1A is its role in the regulation of the cytoskeleton. The cytoskeleton is the structure that surrounds the cell and is involved in cell mechanics, as well as the regulation of cell division and differentiation. TOR1A is known to be involved in the regulation of the cytoskeleton by promoting the formation of microtubules, which are the protein structures that make up the cytoskeleton.

In addition to its role in cytoskeletal regulation, TOR1A has also been shown to be involved in the regulation of several other cellular processes that are important for brain development and function. For example, TOR1A has been shown to be involved in the regulation of protein synthesis, cell adhesion, and neurotransmitter release.

Given its involvement in so many cellular processes that are important for brain development and function, TOR1A is a promising drug target. Researchers are currently working to identify small molecules that can inhibit the activity of TOR1A and prevent its development into a neurodegenerative disease. These small molecules may be used to treat a variety of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its potential as a drug target, TOR1A has also been identified as a potential biomarker for neurodegenerative diseases. The TOR1A gene has been shown to be expressed in the brains of individuals with Alzheimer's disease and other neurodegenerative diseases. This suggests that TOR1A may be a useful biomarker for the diagnosis and progression of these diseases.

Overall, TOR1A is a gene that has the potential to be a drug target and biomarker for neurodegenerative diseases. Further research is needed to understand its full function and to develop small molecules that can inhibit its activity.

Protein Name: Torsin Family 1 Member A

Functions: Protein with chaperone functions important for the control of protein folding, processing, stability and localization as well as for the reduction of misfolded protein aggregates. Involved in the regulation of synaptic vesicle recycling, controls STON2 protein stability in collaboration with the COP9 signalosome complex (CSN). In the nucleus, may link the cytoskeleton with the nuclear envelope, this mechanism seems to be crucial for the control of nuclear polarity, cell movement and, specifically in neurons, nuclear envelope integrity. Participates in the cellular trafficking and may regulate the subcellular location of multipass membrane proteins such as the dopamine transporter SLC6A3, leading to the modulation of dopamine neurotransmission. In the endoplasmic reticulum, plays a role in the quality control of protein folding by increasing clearance of misfolded proteins such as SGCE variants or holding them in an intermediate state for proper refolding. May have a redundant function with TOR1B in non-neural tissues

The "TOR1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TOR1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets